Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
IPO Year: 2021
Exchange: NASDAQ
Website: talaristx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/20/2022 | $18.00 | Buy | H.C. Wainwright |
| 7/5/2022 | $20.00 → $8.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/12/2021 | $21.00 → $22.00 | Outperform | SVB Leerink |
Combined Company to Trade on Nasdaq Under Ticker "TRML"Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") today announced the results of the special meeting of its stockholders held on October 17, 2023. At the special meeting, Talaris' stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Talaris' common stock to the stockholders of Tourmaline Bio, Inc. ("Tourmaline") pursuant to the terms of the Agreement and Plan of Merger, dated as of June 22, 2023, pursuant to which a direct wholly owned subsidiary of Talaris will merge with a
Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Tourmaline Bio, Inc. ("Tourmaline") pursuant to the Agreement and Plan of Merger, dated June 22, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.5118 per share of Talaris common stock, will be payable in cash. The exact amount of the sp
NEW YORK and BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") announced today NYBCe's acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky. The acquisition of both locations, combined with NYBCe's Comprehensive Cell Solutions (CCS) vast cell sourcing and collection network, accelerates the delivery of a fully integrated vein-to-vein cell and gene therapy development and manufacturing solution for the continental United States (US), capable of serving the bi
All three FREEDOM-1 patients treated with FCR001 who are more than 12 months post-transplant have been successfully weaned off chronic anti-rejection drugs All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date have achieved and maintained >50% T-cell chimerism, a potential biomarker predictive of achieving tolerance Conference call scheduled for today at 8:00 a.m. ET BOSTON and LOUISVILLE, Ky., June 30, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood diso
Real-world, retrospective analysis of Phase 2 patients versus matched controls finds FCR001-treated patients have improved kidney function and fewer cardiometabolic complications than patients on immunosuppression after 5 years In long-term follow up of Phase 2 patients, all patients originally weaned off IS have continued to remain off IS without rejecting their donated kidney Update on FREEDOM-1 study originally planned for June 8 now rescheduled to June 30 BOSTON and LOUISVILLE, Ky., June 07, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the sta
BOSTON and LOUISVILLE, Ky., June 01, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced it will host a conference call to discuss its presentations at the American Transplant Congress (ATC) and provide a data update from its ongoing Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients. The conference call will be held on June 8, 2022 at 8:00 a.m. ET. To access the conference call, the dial-in numbers are 1-855-605-1739 for domestic callers and 1-914-9
Company will share first clinical update on Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipientsPoster with additional data from Phase 2 study follow-up to be presented at ASNTalaris to host investor conference call on November 4, 2021, to discuss data BOSTON and LOUISVILLE, Ky., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company, today announced upcoming data presentations at the American Society of Nephrology (ASN) Kidney Week 2021, taking place November 4-7, 2021. In a poster being presented at the ASN meeting, Talaris will share data from continued long-term follow-up of patients treated in
H.C. Wainwright initiated coverage of Talaris Therapeutics with a rating of Buy and set a new price target of $18.00
Morgan Stanley downgraded Talaris Therapeutics from Overweight to Equal-Weight and set a new price target of $8.00 from $20.00 previously
SVB Leerink reiterated coverage of Talaris Therapeutics with a rating of Outperform and set a new price target of $22.00 from $21.00 previously
Combined Company to Trade on Nasdaq Under Ticker "TRML"Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") today announced the results of the special meeting of its stockholders held on October 17, 2023. At the special meeting, Talaris' stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Talaris' common stock to the stockholders of Tourmaline Bio, Inc. ("Tourmaline") pursuant to the terms of the Agreement and Plan of Merger, dated as of June 22, 2023, pursuant to which a direct wholly owned subsidiary of Talaris will merge with a
Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Tourmaline Bio, Inc. ("Tourmaline") pursuant to the Agreement and Plan of Merger, dated June 22, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.5118 per share of Talaris common stock, will be payable in cash. The exact amount of the sp
NEW YORK and BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") announced today NYBCe's acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky. The acquisition of both locations, combined with NYBCe's Comprehensive Cell Solutions (CCS) vast cell sourcing and collection network, accelerates the delivery of a fully integrated vein-to-vein cell and gene therapy development and manufacturing solution for the continental United States (US), capable of serving the bi
NEW YORK, July 15, 2023 (GLOBE NEWSWIRE) -- Kaleyra, Inc. (NYSE:KLR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of KLR to Tata Communications Limited for $7.25 per share in cash. If you are a KLR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Conformis Inc. (NASDAQ:CFMS) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of CFMS to Restor3d, Inc. for $2.27 per share in cash.
Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline's anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) Combined company expected to have approximately $210 million of cash at the transaction close, including approximately $75 million from a concurrent private placement with leading life sciences investors Strong balance sheet expected to support three clinical trials for TOUR006 including a Phase 2b trial in TED, a Phase 2 basket trial in additional TED cohorts, and a Phase 2 trial in ASCVD Talaris stockholders expected to receive approximately $3.43 per Talaris share,
BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and President effective as of today. Ms. Fenton, who will continue as Talaris's Chief Financial Officer, succeeds Chief Executive Officer Scott Requadt who will be leaving the Company as part of a planned workforce reduction, as previously announced by the Company. "On behalf of the board, I would like to thank Scott for his unwavering commitment to patients and to Talaris over the past four and a half years," said Francois Nader, MD, Chairman of the Talaris Therapeutics Board of Directors. "I welcome M
BOSTON and LOUISVILLE, Ky., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), today announced that it has completed a review of its business and program prospects. Based on this review, Talaris has decided to discontinue its FREEDOM-1 and FREEDOM-2 clinical trials evaluating FCR001's ability to induce durable tolerance in living donor kidney transplant recipients. This decision was primarily attributable to the pace of enrollment and the associated timeline to critical milestones. The company will continue to enroll its FREEDOM-3 Phase 2 clinical trial evaluating FCR001's ability to induce tolerance in scleroderma. The Company has initiated a comprehensive review
BOSTON and LOUISVILLE, Ky., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference being held virtually on Tuesday, November 29, 2022 at 4:20 PM ET. A live webcast of the presentation will be available on the investors section of the Talaris website at www.talaristx.com. After the live webcast, the event will remain archived o
Enrollment and dosing continue in the Phase 3 FREEDOM-1 trial of FCR001 in living donor kidney transplant (LDKT) patients Two presentations at the 2022 American Society of Nephrology (ASN) Annual Meeting Strong cash balance with expected runway through 2024 BOSTON and LOUISVILLE, Ky., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today reported financial results for the three- and nine-month periods ended September 30, 2022 and provided an update on its business. "Patient
BOSTON and LOUISVILLE, Ky., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, presented new data characterizing the mechanisms of FCR001-induced immune tolerance in two oral presentations at the 2022 American Society of Nephrology (ASN) Annual Meeting. The first presentation reported on transcriptional changes following successful tolerization with FCR001. Urinary cell mRNA profiling was conducted on 19 patients tolerized with FCR001 in the Company's Phase 2 clinical trial and 15
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
3 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13D/A - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13D/A - Tourmaline Bio, Inc. (0001827506) (Subject)
8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
424B5 - Tourmaline Bio, Inc. (0001827506) (Filer)
424B5 - Tourmaline Bio, Inc. (0001827506) (Filer)
8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
S-8 - Tourmaline Bio, Inc. (0001827506) (Filer)
8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and President effective as of today. Ms. Fenton, who will continue as Talaris's Chief Financial Officer, succeeds Chief Executive Officer Scott Requadt who will be leaving the Company as part of a planned workforce reduction, as previously announced by the Company. "On behalf of the board, I would like to thank Scott for his unwavering commitment to patients and to Talaris over the past four and a half years," said Francois Nader, MD, Chairman of the Talaris Therapeutics Board of Directors. "I welcome M
All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >50% T-cell chimerism, and all three patients who were dosed at least 12 months post-transplant have discontinued their chronic anti-rejection drugs Multiple oral and poster presentations at the American Transplant Congress (ATC) 2022 highlighted key research findings and long-term Phase 2 follow up Strong cash balance with expected runway through 2024 BOSTON and LOUISVILLE, Ky., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform
BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced the appointment of independent director Karen Smith, M.D., Ph.D., MBA, LLM to the Company's Board of Directors. "Karen's long track record of developing and commercializing novel therapies and her wide-ranging industry experience make her a valuable addition to our Board of Directors," said Francois Nader, M.D., Chairman of the Board of Talaris. "I am pleased to welcome her to the team an